Literature DB >> 11375957

Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.

P Laurent-Puig1, P Legoix, O Bluteau, J Belghiti, D Franco, F Binot, G Monges, G Thomas, P Bioulac-Sage, J Zucman-Rossi.   

Abstract

BACKGROUND & AIMS: To evaluate how characterization of genetic alterations can help in the elucidation of liver carcinogenesis pathways, 137 tumors were analyzed.
METHODS: High-density allelotype, p53, Axin1, and beta-catenin gene mutations were determined. Alterations were analyzed according to clinical parameters.
RESULTS: Tumors could be divided into 2 groups according to chromosome stability status. In the first group, demonstrating a chromosome stability, beta-catenin mutation associated with chromosome 8p losses were frequently found as the single genetic alterations. beta-catenin mutations were associated with large tumor size and with negative hepatitis B virus status. In the second group, demonstrating a chromosome instability, the most frequent allelic losses were on chromosome 1p, 4q, 6q, 9p, 13q, 16p, 16q, and 17p; Axin1 and p53 were frequently mutated. All of these alterations, except losses on 6q and 9p, were associated with hepatitis B virus infection. P53 mutations, 17p, 13q losses, and a high value of the fractional allelic loss index were associated with poor differentiated tumors, independently of risk factors. Finally, in the whole series, chromosome 9p and 6q losses were associated with poor prognosis.
CONCLUSIONS: Two main pathways defined by genetic alterations show different risk factors and clinical characteristics. Furthermore, loss of chromosome 9p or 6q is an independent prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375957     DOI: 10.1053/gast.2001.24798

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  157 in total

1.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 2.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

3.  R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.

Authors:  Jaideep Behari; Gang Zeng; Wade Otruba; Michael D Thompson; Peggy Muller; Amanda Micsenyi; Sandeep S Sekhon; Lorenzo Leoni; Satdarshan P S Monga
Journal:  J Hepatol       Date:  2006-12-21       Impact factor: 25.083

4.  New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis.

Authors:  Kevin David Shield; Claire Marant Micallef; Catherine de Martel; Isabelle Heard; Francis Megraud; Martyn Plummer; Jérôme Vignat; Freddie Bray; Isabelle Soerjomataram
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

Review 5.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

6.  Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence.

Authors:  Frederique Caillot; Celine Derambure; Paulette Bioulac-Sage; Arnaud Francois; Michel Scotte; Odile Goria; Martine Hiron; Maryvonne Daveau; Jean Philippe Salier
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 7.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 8.  Cancer stem cells and hepatocellular carcinoma.

Authors:  Zhixing Yao; Lopa Mishra
Journal:  Cancer Biol Ther       Date:  2009-09       Impact factor: 4.742

Review 9.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

10.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.